<DOC>
	<DOCNO>NCT01090830</DOCNO>
	<brief_summary>The purpose study establish safe dose investigational medication Belinostat administer standard care chemotherapy regimen bevacizumab , carboplatin , paclitaxel . Further study examine short long-term effect ( 2 year ) medication participant 's disease status overall survival .</brief_summary>
	<brief_title>Safety Efficacy Belinostat When Used With Standard Care Chemotherapy Untreated Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This Phase Ib/II , single center , open label , dose-finding study evaluate use Belinostat give standard care chemotherapy patient untreated , non-small cell lung cancer ( NSCLC ) . In Phase Ib portion , dose limit toxicity evaluation use determine maximum tolerate dose ( MTD ) Belinostat give fix dos bevacizumab , carboplatin , paclitaxel ( BelCap-B regimen ) . Three dose level Belinostat propose ( 600mg/kg , 800mg/kg , 1000mg/kg ) . Determination MTD basis establish set dose phase II component study . The phase II portion study include drug safety evaluation preliminary assessment efficacy Belinostat use specify induction maintenance regimen . Response evaluate RECIST criterion . Additional analysis do estimate time response , progression free survival , median survival , overall survival ( OS ) study participant 2 year post-initiation cycle 1 . Based standard 3 x 3 statistical design , phase Ib portion may accrue 3 12 participant . Phase II minimum sample size 10 maximum 16 patient . Participants complete Phase I portion able advance Phase II , evaluable Phase II objective .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histologically cytologically document NSCLC confirm . Has advance NSCLC ( Stage IV ) , previously treat chemotherapy regiment ( prior adjuvant chemotherapy and/or chemotherapy/radiation Stage III allow ) . Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . Life expectancy &gt; 3 month Must return baseline grade 1 adverse event acute toxicity relate prior therapy Adequate immune multisystem organ function ( evidenced urine blood value within specified parameter ) . Brain meningeal metastasis . Note , patient adequately treat brain metastasis , e.g . surgically resect , adequately control radiotherapy , residual neurological symptom due metastasis steroid treatment require , enrol . If clinical suspicion , adequate investigation perform rule brain metastasis meningeal involvement . History previous malignancy within 5 year exception nonmetastatic nonmelanoma skin cancer cervical carcinoma situ . Prior systemic therapy malignancy must complete least 5 year treatment allow . Lung carcinoma squamous cell histology ( mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible ; sputum cytology alone acceptable ) . History hemoptysis within 3 month prior enrollment Current recent ( within 10 day enrollment ) use aspirin ( &gt; 325 mg/day ) chronic use nonsteroidal antiinflammatory medication . Prior systemic antitumor therapy Stage IV lung cancer . Note , prior radiotherapy allow provide treatment complete least 2 week enrollment . Prior surgery allow complete least 4 week enrollment . Treatment investigational agent within 2 week prior enrollment . Significant vascular disease ( e.g. , aortic aneurysm , history aortic dissection ) clinically significant peripheral vascular disease . Hypertension control medical therapy . Significant cardiovascular disease , myocardial infarction within past 6 month , unstable angina , unstable arrhythmia need antiarrhythmic therapy ( use medication control heart rate patient atrial fibrillation allow , stable medication least last month prior enrollment , evidence acute ischemia electrocardiogram ) . Marked baseline prolongation QT/QTc interval require use concomitant medication may cause Torsade de Pointes Significant , nonhealing wound , acute nonhealing ulcer , bone fracture within 3 month fracture . Undergone major surgery within 4 week plan initiation cycle 1 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day enrollment . History gastrointestinal bleeding within 3 month prior enrollment . Known hypersensitivity either platinum compound paclitaxel , component study medication , inability desensitization . Peripheral neuropathy NCI â‰¥ Grade 2 . Coexisting active severe infection coexist medical condition likely interfere trial procedure . Known infection HIV , know active Hepatitis B C infection . Pregnant lactating . willing use effective contraception study 6 month postcompletion last cycle administer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Belinostat</keyword>
	<keyword>carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Neoplasms , Pulmonary</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Event Free Survival</keyword>
	<keyword>Disease free survival</keyword>
	<keyword>Progression Free Survival</keyword>
	<keyword>Histone Deacetylase Inhibitors</keyword>
	<keyword>Treatment Efficacy</keyword>
</DOC>